Table 2.
Comparison of HE4, CA125, ROMA, and CPH-I in different groups.
| Benign | BOT I+II | EOC I+II | |||||||
|---|---|---|---|---|---|---|---|---|---|
| All | Pre-M | Post-M | All | Pre-M | Post-M | All | Pre-M | Post-M | |
| HE4 (pmol/L) | 43.8 (39.2-49.1) | 43.9 (38.9-49.1) | 43.5 (41.5-55.9) | 48.4 (41.8-56.5)∗ | 47.6 (41.2-56.0)∗ | 50.1 (45.4-61.4) | 80.3 (55.3-171.2)∗^ | 64.2 (50.7-136.4)∗^ | 95.0 (67.4-221.0)∗^ |
| CA125 (U/mL) | 24.9 (15.2-55.0) | 25.3 (16.2-61.0) | 13.6 (10.5-33.7) | 34.1 (19.5-69.0)∗ | 35.6 (21.5-67.3)# | 22.2 (16.9-189.8) | 95.1 (35.6-234.5)∗^ | 88.5 (35.7-182.1)∗^ | 104.5 (33.4-320.7)∗ |
| ROMA (%) | 6.03 (4.5-8.0) | 5.7 (4.4-7.4) | 11.5 (8.1-16.5) | 7.5 (5.3-12.0)∗ | 6.7 (5.1-10.3)∗ | 15.4 (11.7-56.5) | 30.7 (10.6-65.6)∗^ | 14.6 (8.7-49.5)∗^ | 59.7 (28.6-81.5)∗^ |
| CPH-I (%) | 1.0 (0.7-2.3) | 1.0 (0.7-2.2) | 1.8 (0.9-2.5) | 1.6 (0.9-3.1)∗ | 1.4 (0.9-2.8)# | 2.3 (1.4-16.1) | 11.3 (3.3-42.6)∗^ | 7.2 (2.3-26.0)∗^ | 25.1 (7.4-59.9)∗^ |
Note: data are presented as the median (interquartile range). ∗P < 0.01 and #P < 0.05 compared with benign corresponding subgroups; ^P < 0.01 compared with BOT I+II corresponding subgroups. Abbreviations: Pre-M = premenopausal; Post-M = postmenopausal; BOT I+II = borderline ovarian tumors in FIGO stages I and II; EOC I+II = epithelial ovarian cancer in FIGO stages I and II.